Chiesi France receives Choose France’s “Contribution au plan de relance (Contribution to Stimulus Plan)” special award from the Minister for Territorial Cohesion and Relations with Local Authorities
19 Gennaio 2022
A new clinical framework redefines the diagnosis of COPD Exacerbations
16 Dicembre 2021
Chiesi Group focuses on biological drugs: an investment of 85 million euros for an international centre of excellence in Parma
14 Dicembre 2021
Chiesi Group Headquarters takes centre stage in the monograph “SPAZIO LAVORO ARCHITETTURA” (SPACE WORK ARCHITECTURE) Electaarchitettura editions
13 Dicembre 2021
Chiesi and UCB enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
30 Novembre 2021
Chiesi Research Centre: 10 years’ scientific innovation serving the community
18 Ottobre 2021
Chiesi receives positive ESG rating from independent rating agency Cerved
23 Settembre 2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07 Settembre 2021
ERS Congress 2021 – Important updates on Asthma and COPD treatments presented at the Symposium organised by Chiesi “Unlock Every Breath: finding the right key to improve Respiratory Therapy”
06 Settembre 2021
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
